Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study (Journal article)

Vlachoyiannopoulos, P. G./ Kanellopoulos, P. G./ Ioannidis, J. P./ Tektonidou, M. G./ Mastorakou, I./ Moutsopoulos, H. M.


Full metadata record
DC FieldValueLanguage
dc.contributor.authorVlachoyiannopoulos, P. G.en
dc.contributor.authorKanellopoulos, P. G.en
dc.contributor.authorIoannidis, J. P.en
dc.contributor.authorTektonidou, M. G.en
dc.contributor.authorMastorakou, I.en
dc.contributor.authorMoutsopoulos, H. M.en
dc.date.accessioned2015-11-24T19:34:28Z-
dc.date.available2015-11-24T19:34:28Z-
dc.identifier.issn1462-0324-
dc.identifier.urihttp://olympias.lib.uoi.gr/jspui/handle/123456789/23623-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAntibodies, Anticardiolipin/blooden
dc.subjectAntiphospholipid Syndrome/blood/*complicationsen
dc.subjectArteriosclerosis/blood/*etiologyen
dc.subjectArthritis, Rheumatoid/complicationsen
dc.subjectCarotid Artery Diseases/etiologyen
dc.subjectFemaleen
dc.subjectFemoral Arteryen
dc.subjectGlucocorticoids/adverse effectsen
dc.subjectHumansen
dc.subjectLipids/blooden
dc.subjectLipoproteins, LDL/blooden
dc.subjectLupus Erythematosus, Systemic/blood/*complicationsen
dc.subjectOdds Ratioen
dc.subjectPremenopause/blooden
dc.subjectRisk Factorsen
dc.titleAtherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled studyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/12709540-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2003-
heal.abstractOBJECTIVE: To evaluate whether premenopausal women with antiphospholipid syndrome (APS) or systemic lupus erythematosus (SLE) have increased prevalence of atherosclerosis after adjustment has been made for known cardiovascular risk factors. METHODS: We evaluated premenopausal women with APS in comparison with age-matched groups of patients with SLE [positive or negative for anticardiolipin (aCL) antibodies] or rheumatoid arthritis (RA), and healthy subjects. Thirty-three subjects in each group were assessed for cardiovascular risk factors, including a detailed lipid profile. Ultrasonography of carotid and femoral arteries assessed the intima-media thickness (IMT) and the presence of atherosclerotic plaque. RESULTS: Atherosclerotic plaques were detected in 5, 2, 4, 1 and 1 subject in the five groups respectively. APS patients had significantly more affected vessels than RA patients and healthy controls (P=0.042 and P=0.016, respectively), but not compared with SLE patients. No consistent differences in IMT, traditional cardiovascular risk factors or lipid parameters were detected among the five groups. The odds for atherosclerosis independently increased 1.19-fold per year of increasing age [95% confidence interval (CI) 1.08-1.31; P=0.001), 1.019-fold per 1 mg/dl increase in low-density lipoprotein (LDL) (95% CI 1.003-1.036; P=0.020), 1.035-fold per additional 1 g of methylprednisolone equivalent cumulative corticosteroid dose (95% CI, 0.996-1.074; P=0.074), and 4.35-fold in the presence of APS or SLE (95% CI 0.75-25.2; P=0.10). Neither aCL nor anti-beta(2)GPI antibodies were associated with atherosclerosis. CONCLUSION: Premenopausal APS and SLE women have an increased prevalence of carotid and femoral plaque that is not accounted for by other predictors of atherosclerosis, including age, lipid parameters and cumulative steroid dose.en
heal.journalNameRheumatology (Oxford)en
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.



 Please use this identifier to cite or link to this item:
http://olympias.lib.uoi.gr/jspui/handle/123456789/23623
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.